期刊文献+

羟基磷灰石法和葡聚糖活性炭法测定雌激素受体的比较 被引量:10

A comparison between HAP and DCC methods for estrogen receptor measurements.
下载PDF
导出
摘要 目的:建立一种比葡聚糖活性炭(DCC)法更灵敏、准确、简便的羟基磷灰石(HAP)法测定雌激素受体(ER)的含量。方法:以SD雌性大鼠子宫胞浆抽提液为材料,用HAP法多点饱和分析和单点饱和分析ER含量;比较在测定反应中总蛋白量对HAP法和DCC法测定值的影响,并比较两者在30例乳腺癌和30例子宫肌瘤中ER测定值的差异。结果:大鼠子宫胞浆ER含量为135fmol/mg蛋白,Kd=0.58nM。当测定反应中总蛋白量低于200μg时,DCC法测定值严重失真,而HAP法在总蛋白量为50μg时仍能准确测出真实值。在30例乳腺癌和30例子宫肌瘤ER测定值中,当ER含量较低时,DCC法测定值偏低甚至有假阴性.而ER含量高时两者接近。在ER含量较高时,两者测定值相近。结论:HAP法比DCC法灵敏、可靠。用以测定甾体激素高非特异性结合的靶组织与非靶组织中的ER低含量时,HAP法更有价值。 Objective To establish HAP assay a powerful method to determine estrogen receptor more sensitively,more accurately and more conveniently than that of DCC assay. Methods Uterine cytosol extracts from SD female rats were used to establish the HAP multi point saturation assay and HAP single point saturation assay.The authors examined the effect of total protein level on HAP and DCC assays and compared the ER values measured by HAP and DCC in 30 breast cancer cases and 30 leiomyoma cases respectively. Results The ER value in rat uterine cytosol extract was 135 fmol/mg cytosol protein.Kd value was 0.58nM.HAP assay could exactly determine ER value when total protein was less than 50μg,but DCC assay could not determine even when total protein level was less than 200μg.When ER level in 30 breast cancer cases and 30 leiomyoma cases was low,the value examined by DCC assay was lower than its real value,but when ER level was high enough,the value measured by DCC and HAP were almost equal to each other. Conclusions HAP assay is a more sensitive,more accurate method than that of DCC assay and plays a more valuable role on determinating low ER value in all kinds of steroid target and nontarget tumor tissues with high nonspecific binding.
出处 《现代妇产科进展》 CSCD 1996年第4期321-323,共3页 Progress in Obstetrics and Gynecology
关键词 羟基磷灰石 葡聚糖活性炭 雌激素受体 测定 肿瘤 Hydroxylapatite(HAP) Dextran coated charcoal(DCC) Receptors,estrogen
  • 相关文献

同被引文献59

  • 1王亚东,陈小玉,吴逸明,许东,许玉宝.汞、铬和锰化合物雌激素样作用的实验研究[J].卫生研究,2005,34(1):49-51. 被引量:4
  • 2Ross JS, Hatzis C, Symmans WF, et al. Commercialized multigene predictors of clinical outcome for breast cancer [ J ] . Oncologist, 2008, 13(5): 477-493.
  • 3Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer [ J ] . Cancer Res, 2002, 1, 62(3): 632-635.
  • 4Howe LR. Inflammation and breast cancer. Cyelooxygenase/prostaglandin signaling and breast cancer[J].Breast Cancer Res, 2007, 9(4): 210.
  • 5Chow LW, Yip AY, Loo WT, et al. Celecoxib anti-aromatase neoadjuvant(CAAN) trial for locally advanced breast cancer [ J ] . J Steroid Biochem Mol Biol, 2008, 111(1-2): 13-17; Epub, 2008, 20.
  • 6Blair RM, Fang H, Branham W S, et al. The estrogen receptor relative binding affinities of 188 natural and xenochemicals : structural diversity of ligands[J]. Toxicol Sci, 2000, 54 (1): 138.
  • 7Deil P, Schulz T, Smolnikar K, et al. Ability of xeno- and phytoestrogens to modulate expression of estrogen-sensitive genes in rat uterus: estrogenicity profiles and uterotropic activity [J ]. J Steroid Biochem Mol Biol, 2000, 73 (1-2): 1-10.
  • 8Soto AM, Maffini MV, Schaeberle CM, et al. Strengths and weaknesses of in vitro assays for estrogenic and androgenic activity[J]. Best Pract Res Clin Endocrinol Metab, 2006,20:15-33.
  • 9Kavlock RJ, Daston GP, DeRosa C, et al. Research needs for the risk assessment of health and environmental effects of endocrine disruptors: a report of the U. S. EPA-sponsored workshop [J]. Environ Health Perspect, 1996, 104:715-740.
  • 10IPCS. The International Programme on Chemical Safety (IPCS): global assessment of the state-of-the-science of endocrine disruptors [R]. WHO, 2002, WHO/PCS/EDC/02.2.

引证文献10

二级引证文献55

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部